Home Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of July 2022).

In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.

Program (Target) Potential Indication(s) First-in-Human (Phase 1) Proof-of-Concept
(Phase 2)
Pivotal
(Phase 3)
Major Market Rights
MGC018
(B7-H3)
mCRPC, NSCLC, SCCHN, Melanoma
placeholder
Multiple Solid Tumors
(+lorigerlimab)
placeholder
Lorigerlimab
(PD-1 × CTLA-4)
MSS CRC, NSCLC, mCRPC, Melanoma
placeholder
Tebotelimab
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
placeholder
Greater China
IMGC936
(ADAM9)
Multiple Solid Tumors
placeholder
50/50
MGD024
(CD123 × CD3)
CD123+ Heme Malignancies
placeholder
Plan to initiate in mid-2022a

Oncology
MGC018 (B7-H3)
mCRPC, NSCLC, SCCHN, Melanoma
Phase 1 Phase 2 Phase3
placeholder
Multiple Solid Tumors (+lorigerlimab)
Phase 1 Phase 2 Phase3
placeholder

Major Market Rights:

Lorigerlimab
(PD-1 × CTLA-4)
MSS CRC, NSCLC, mCRPC, Melanoma
Phase 1 Phase 2 Phase3
placeholder

Major Market Rights:

Tebotelimab
(PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
Phase 1 Phase 2 Phase3
placeholder

Major Market Rights:

Greater China
IMGC936
(ADAM9)
Multiple Solid Tumors
Phase 1 Phase 2 Phase3
placeholder

Major Market Rights:

50/50
MGD024
(CD123 × CD3)
CD123+ Heme Malignancies
Phase 1 Phase 2 Phase3
placeholder

Plan to initiate in mid-2022a

Major Market Rights:

MGD = DART MGC = ADC

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close